Assessing Risk and Individualizing Therapy in HR+/HER2- Early Breast Cancer

Download these slides from an expert-led symposium reviewing the latest advances in targeted therapy for HR-positive/HER2-negative early-stage breast cancer.
Komal Jhaveri, MD
Program Director
Erica Mayer, MD, MPH
Format: Microsoft PowerPoint (.ppt)
File Size: 778 KB
Released: June 6, 2022

Acknowledgements

Provided by Clinical Care Options, LLC

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Supported by educational grants from
Lilly
Novartis Pharmaceuticals Corporation
Sanofi Genzyme

Related Content

Commentary from Dr Heather McArthur on latest developments in managing early-stage breast cancer (EBC), from Clinical Care Options (CCO)

Heather McArthur, MD, MPH
Program Director
Released: August 4, 2022

Downloadable slideset from a workshop series from Clinical Care Options (CCO) on the management of NTRK and RET-altered malignancies.

Alexander Drilon, MD
Program Director
Thomas Stinchcombe, MD
Program Director
Released: August 4, 2022

Downloadable slideset from a live webinar presented by Jamie Carroll, MSN on managing adverse events and promoting adherence to CDK4/6 and PI3K inhibitors, from Clinical Care Options (CCO)

Robert T. Carroll, PhD(c), RN, ACRN Released: July 26, 2022

Downloadable slideset from a live webinar presented by Sarah Hurvitz, MD, on selecting and sequencing targeted therapy for HR+/HER2- breast cancer, from Clinical Care Options (CCO)

Sara Hurvitz, MD, FACP Released: July 26, 2022

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue

Cookie Settings